Video

Treatment Strategies for Patients with R/R LBCL

Author(s):

Manali Kamdar, MD,Matthew A. Lunning, DO, FACP

Experts provide their perspective on the treatment landscape for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

Related Videos
Minoo Battiwalla, MD, MS
David C. Fisher, MD
Alex Herrera, MD
Grzegorz S. Nowakowski, MD
Francisco Hernandez-Ilizaliturri, MD, professor, oncology, Department of Medicine—Lymphoma; director, Lymphoma Research, head, Lymphoma Translational Research Lab; associate professor, Department of Immunology, Roswell Park Comprehensive Cancer Center; clinical professor, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Amitkumar Mehta, MD
Grzegorz S. Nowakowski, MD
Jasmin M. Zain, MD
Grzegorz S. Nowakowski, MD
Grzegorz S. Nowakowski, MD
Related Content
CAR T Cells in R/R Non-Hodgkin Lymphoma | Image Credit: © Tatiana Shepleva - stock.adobe.com
November 14th 2024

Transposon-Based BAFF CAR T Cells Show Early Efficacy, Safety in R/R Non-Hodgkin Lymphoma

Matthew Lunning, DO, FACP
December 21st 2023

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

OncLive's Top 5 Stories of the Week in Oncology
November 9th 2024

The OncFive: Top Oncology Articles for the Week of 11/3

Matthew Lunning, DO, FACP
October 30th 2023

Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma

Michel Delforge, MD, PhD
November 1st 2024

Indirect Comparison Shows Superiority of Cilta-Cel vs SOC Regimens in Lenalidomide-Refractory Myeloma

Recap of every episode of OncLive On Air® that aired in October 2024
November 1st 2024

Revisit Every OncLive On Air Episode From October 2024